Skip to main content

Table 2 Univariate analysis to identify preoperatively clinical and echocardiographic variables to predict development of SVD in patients with Mitroflow bioprosthesis

From: Influence of Mitroflow bioprosthesis structural valve deterioration on cardiac morbidity

  Total (n = 211) SVD (n = 53)
HR P-value HR P-value
Mitroflow valve size 21 1.13 0.41 0.65 0.16
Sex (man) 1.19 0.27 1.13 0.72
Age (ref: 60–69 years) 1.00    
 70–79 years 1.07 0.78 1.21 0.55
 > 80 years 0.99 0.98 1.71 0.29
BSA (> 1.73 m2) 1.15 0.38 1.87 0.25
NYHA (ref: I) 1.00    
 II 1.20 0.48 1.18 0.73
 III 1.40 0.18 1.29 0.55
 IV 2.10 0.06 NA  
EF (< 50%) 1.12 0.50 0.80 0.51
Smoker (ref: no) 1.00    
 Previously 1.57 0.01 1.14 0.69
 Active 1.41 0.08 1.30 0.48
Diabetes (yes) 0.99 0.95 1.18 0.69
IHD (yes) 1.07 0.61 0.99 0.97
Hypertension (yes) 0.96 0.79 1.10 0.73
  1. BSA Body surface area, NYHA New York Heart Association, EF Ejection fraction, IHD Ischemic heart disease